ESR1 and breast cancer: In 2022, Aggelopoulos et al. investigated the effects of direct and indirect CAP treatment, facilitated by advantageous nanosecond pulsed discharge, on breast cancer cells with varying malignant phenotypes and estrogen receptor (ER) status.